Literature DB >> 16940135

Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease?

Irfan A Dhalla1, Muhammad M Mamdani, Andrew E Simor, Alex Kopp, Paula A Rochon, David N Juurlink.   

Abstract

Limited evidence suggests that broad-spectrum fluoroquinolones such as gatifloxacin and moxifloxacin are more likely to cause Clostridium difficile-associated disease than levofloxacin. In a population-based case-control study of outpatients prescribed fluoroquinolones, we found no increased risk of C. difficile-associated disease requiring hospitalization among patients prescribed gatifloxacin or moxifloxacin compared to levofloxacin.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16940135      PMCID： PMC1563507          DOI： 10.1128/AAC.00592-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  29 in total

1.  Antibiotics and Clostridium difficile.

Authors:  S L Gorbach
Journal:  N Engl J Med       Date:  1999-11-25       Impact factor: 91.245

2.  Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data.

Authors:  S Schneeweiss; J D Seeger; M Maclure; P S Wang; J Avorn; R J Glynn
Journal:  Am J Epidemiol       Date:  2001-11-01       Impact factor: 4.897

3.  Creation of a clinical classification. International statistical classification of diseases and related health problems--10th revision, Australian modification (ICD-10-AM).

Authors:  K Innes; J Hooper; M Bramley; P DahDah
Journal:  Health Inf Manag       Date:  1997 Mar-May       Impact factor: 3.185

4.  Drug-drug interactions among elderly patients hospitalized for drug toxicity.

Authors:  David N Juurlink; Muhammad Mamdani; Alexander Kopp; Andreas Laupacis; Donald A Redelmeier
Journal:  JAMA       Date:  2003-04-02       Impact factor: 56.272

5.  Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications.

Authors:  Ramsey M Dallal; Brian G Harbrecht; Arthur J Boujoukas; Carl A Sirio; Linda M Farkas; Kenneth K Lee; Richard L Simmons
Journal:  Ann Surg       Date:  2002-03       Impact factor: 12.969

6.  Long-term MI outcomes at hospitals with or without on-site revascularization.

Authors:  D A Alter; C D Naylor; P C Austin; J V Tu
Journal:  JAMA       Date:  2001-04-25       Impact factor: 56.272

Review 7.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 8.  Quinolone activity against anaerobes.

Authors:  P C Appelbaum
Journal:  Drugs       Date:  1999       Impact factor: 9.546

9.  Epidemiology of Clostridium difficile infection in a large population of hospitalized US military veterans.

Authors:  Anna M Buchner; Amnon Sonnenberg
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

10.  Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum.

Authors:  Gary E Stein; Sharon Schooley; Kerin L Tyrrell; Diane M Citron; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191
View more
  9 in total

1.  Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection.

Authors:  Kevin A Brown; Nagham Khanafer; Nick Daneman; David N Fisman
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

2.  Clostridium difficile-associated diarrhea in a tertiary care medical center.

Authors:  Marilee D Obritsch; Jeffrey S Stroup; Ryan M Carnahan; David N Scheck
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-10

3.  Antibiotic Prescribing Choices and Their Comparative C. Difficile Infection Risks: A Longitudinal Case-Cohort Study.

Authors:  Kevin Antoine Brown; Bradley Langford; Kevin L Schwartz; Christina Diong; Gary Garber; Nick Daneman
Journal:  Clin Infect Dis       Date:  2021-03-01       Impact factor: 9.079

4.  Effects of ciprofloxacin on the expression and production of exotoxins by Clostridium difficile.

Authors:  Michael John Aldape; Aaron Eugene Packham; Drew William Nute; Amy Evelyn Bryant; Dennis Leroy Stevens
Journal:  J Med Microbiol       Date:  2013-02-21       Impact factor: 2.472

Review 5.  Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.

Authors:  Françoise Van Bambeke; Paul M Tulkens
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

6.  Fluoroquinolone-related adverse events resulting in health service use and costs: A systematic review.

Authors:  Laura S M Kuula; Kati M Viljemaa; Janne T Backman; Marja Blom
Journal:  PLoS One       Date:  2019-04-26       Impact factor: 3.240

7.  Corticosteroids Do Not Increase the Likelihood of Primary Clostridioides difficile Infection in the Setting of Broad-Spectrum Antibiotic Use.

Authors:  Travis J Carlson; Anne J Gonzales-Luna; Melissa F Wilcox; Sarah G Theriault; Faris S Alnezary; Pankaj Patel; Bumhee K Ahn; Evan J Zasowski; Kevin W Garey
Journal:  Open Forum Infect Dis       Date:  2021-08-11       Impact factor: 3.835

8.  Increase in Clostridium difficile-related mortality rates, United States, 1999-2004.

Authors:  Matthew D Redelings; Frank Sorvillo; Laurene Mascola
Journal:  Emerg Infect Dis       Date:  2007-09       Impact factor: 6.883

9.  Antimicrobial drugs and community-acquired Clostridium difficile-associated disease, UK.

Authors:  J A Chris Delaney; Sandra Dial; Alan Barkun; Samy Suissa
Journal:  Emerg Infect Dis       Date:  2007-05       Impact factor: 6.883
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.